Results 41 to 50 of about 290,304 (371)

A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract [PDF]

, 2016
Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy has only modest benefit. This multi-centre phase II study was conducted to determine the efficacy of capecitabine in combination with ...
E. Soulis, F. Y. Coxon, J. S. Graham, K. Boyd, L. R. Wall, M. Highley, M. M. Eatock, P. Bützberger-Zimmerli, S. Harden, T. R. J. Evans, T. S. Maughan   +10 more
core   +1 more source

Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial

Journal of Clinical Oncology, 2019
PURPOSE In the multicenter, open-label, phase III FOWARC trial, modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher pathologic complete response rate than fluorouracil plus radiotherapy in ...
Yanhong Deng, P. Chi, P. Lan, Lei Wang, Weiqing Chen, L. Cui, Daoda Chen, Jie Cao, Hongbo Wei, Xiang Peng, Zonghai Huang, Guanfu Cai, R. Zhao, Zhongcheng Huang, Lin Xu, Hongfeng Zhou, Yisheng Wei, Hao Zhang, Jian Zheng, Yan Huang, Zhi-yang Zhou, Yue Cai, L. Kang, Meijin Huang, Xiaojian Wu, J. Peng, D. Ren, Jianping Wang   +27 more
semanticscholar   +1 more source

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. [PDF]

, 2020
Chemotherapy and checkpoint inhibitor immunotherapies are increasingly used in combinations. We determined associations between the presence of anti-PD-1/PD-L1 therapeutic biomarkers and protein markers of potential chemotherapy response.
Arguello, David, Barkauskas, Donald A, Gatalica, Zoran, Kurzrock, Razelle, Nikanjam, Mina, Swensen, Jeff   +5 more
core   +2 more sources

Xanthine Oxidase Inhibitor, Febuxostat Is Effective against 5-Fluorouracil-Induced Parotid Salivary Gland Injury in Rats Via Inhibition of Oxidative Stress, Inflammation and Targeting TRPC1/CHOP Signalling Pathway

Pharmaceuticals, 2022
The current research aimed to examine the ameliorative role of febuxostat (FEB), a highly potent xanthine oxidase inhibitor, against 5-fluorouracil (5-FU)-induced parotid salivary gland damage in rats, as FEB is a pleiotropic drug that has multiple ...
Walaa Yehia Abdelzaher, Mohamed A. Nassan, Sabreen Mahmoud Ahmed, Nermeen N. Welson, Gaber El-Saber Batiha, Hanaa Mohamed Khalaf   +5 more
doaj   +1 more source

Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer [PDF]

, 2012
Background: Data from meta-analyses have shown taxane-containing therapies to be superior to anthracycline-based treatments for high-risk breast cancer. Patients and Methods: The ADEBAR trial was a multicenter phase Ill trial in which patients with lymph
Aivazova-Fuchs, Viktoria, Andergassen, Ulrich, Annecke, Katja, Augustin, Doris, Friese, Klaus, Harbeck, Nadia, Hepp, Philip, Janni, Wolfgang, Jückstock, Julia K., Kiechle, Marion, Mohrmann, Svjetlana, Rack, Brigitte, Salmen, Jessica, Schönherr, Alexandra, Simon, Wolfgang, Wischnik, Arthur, Zwingers, Thomas   +16 more
core   +1 more source

Fluorouracil Supplemented With Oxaliplatin or Irinotecan for Solid Tumors: Indications From Clinical Characteristics and Health Outcomes of Patients

Frontiers in Oncology, 2020
Fluorouracil combined with oxaliplatin (FOLFOX) and fluorouracil combined with irinotecan (FOLFIRI) are both first-line clinical chemotherapy regimens. However, clinicians' selection of FOLFIRI or FOLFOX medication regimens and their effects on patients'
Zhao Qingwei, Zhao Qingwei, Hong Dongsheng, Lv Duo, Lv Duo, Wang Youlei, Yu Songxia, Ye Ziqi, Li Lanjuan   +8 more
doaj   +1 more source

Increased response of oxaliplatin or irinotecan on chemosensitivity to 5-fluorouracil in patients with colorectal cancer [PDF]

Korean Journal of Clinical Oncology, 2014
Purpose: Five-fluorouracil (5-FU) is the basement drug of chemotherapy in patients with colorectal cancer. Recently, 5-FU and oxaliplatin or irinotecan is to be used by merging.
Se Na Cho, Kyung Jong Kim
doaj   +1 more source

A prelude report on molecular docking of HER2 protein towards comprehending anti-cancer properties of saponins from Solanum tuberosum [PDF]

, 2012
Saponins are extensively known for many biological activities e.g. antimicrobial, anti-palatability, anti-cancer and hemolytic. As cancer cells have a more cholesterol-like compound in their membrane structure the saponins bind cholesterol due to their ...
Pratyoosh Shukla, Puneet K. Singh
core   +2 more sources

5-fluorouracil and cardiotoxicity: a review

Therapeutic Advances in Medical Oncology, 2018
Fluoropyrimidines such as 5-fluorouracil (5-FU) form the foundation of a wide variety of chemotherapy regimens. 5-FU is in fact the third most commonly used chemotherapeutic agent in the treatment of solid malignancies across the world.
J. Sara, J. Kaur, Ryan Khodadadi, M. Rehman, R. Lobo, S. Chakrabarti, J. Herrmann, A. Lerman, A. Grothey   +8 more
semanticscholar   +1 more source

COMPARISON OF THE ANTIEMETIC EFFECTIVENESS BETWEEN GRANISETRON AND DEXAMETHASONE WITH ONDANSETRON AND DEXAMETHASONE IN ACUTE-PHASE CHEMOTHERAPY PATIENTS

Folia Medica Indonesiana, 2017
Nausea and vomiting may occur in patients receiving chemotherapy, a condition referred to as chemotherapy-induced nausea and vomiting. The provision of combined dexamethasone and ondansetron or granisetron is the therapeutic management of acute phase ...
Ria Fitrah Arfiani, Dwi Hari Susilo, Budi Suprapti   +2 more
doaj   +1 more source